Janus Henderson Group PLC Has $104.23 Million Holdings in Teva Pharmaceutical Industries Limited (TEVA)

Janus Henderson Group PLC lowered its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 19.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,138,087 shares of the company’s stock after selling 740,856 shares during the quarter. Janus Henderson Group PLC owned about 0.31% of Teva Pharmaceutical Industries Limited worth $104,232,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Sii Investments Inc. WI increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock valued at $214,000 after purchasing an additional 25 shares during the period. Salem Investment Counselors Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock valued at $267,000 after purchasing an additional 32 shares during the period. Bronfman E.L. Rothschild L.P. increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares during the period. Sterling Investment Advisors Ltd. increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after purchasing an additional 100 shares during the period. Finally, First City Capital Management Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. First City Capital Management Inc. now owns 26,670 shares of the company’s stock valued at $856,000 after purchasing an additional 100 shares during the period. Institutional investors own 56.75% of the company’s stock.

Several brokerages have commented on TEVA. Jefferies Group LLC restated a “hold” rating and issued a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. ValuEngine upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Piper Jaffray Companies set a $23.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Friday. Deutsche Bank AG restated a “buy” rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, October 4th. Five equities research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $27.63.

TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/10/10/janus-henderson-group-plc-has-104-23-million-holdings-in-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 15.897 on Tuesday. The company has a 50-day moving average of $16.87 and a 200-day moving average of $26.56. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $45.14. The firm’s market cap is $16.15 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the company posted $1.25 EPS. The firm’s revenue for the quarter was

Several other large investors have also recently made changes to their positions in the business. Sii Investments Inc. WI increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock valued at $214,000 after purchasing an additional 25 shares during the period. Salem Investment Counselors Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock valued at $267,000 after purchasing an additional 32 shares during the period. Bronfman E.L. Rothschild L.P. increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares during the period. Sterling Investment Advisors Ltd. increased its stake in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after purchasing an additional 100 shares during the period. Finally, First City Capital Management Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. First City Capital Management Inc. now owns 26,670 shares of the company’s stock valued at $856,000 after purchasing an additional 100 shares during the period. Institutional investors own 56.75% of the company’s stock.

Several brokerages have commented on TEVA. Jefferies Group LLC restated a “hold” rating and issued a $26.00 price target (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. ValuEngine upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Piper Jaffray Companies set a $23.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Friday. Deutsche Bank AG restated a “buy” rating and issued a $28.00 price target (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, October 4th. Five equities research analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $27.63.

TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/10/10/janus-henderson-group-plc-has-104-23-million-holdings-in-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 15.897 on Tuesday. The company has a 50-day moving average of $16.87 and a 200-day moving average of $26.56. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $45.14. The firm’s market cap is $16.15 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the previous year, the company posted $1.25 EPS. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. Analysts predict that Teva Pharmaceutical Industries Limited will post $4.26 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were paid a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 2.16%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is presently -15.36%.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply